{"id":124691,"date":"2026-09-02T22:20:58","date_gmt":"2026-09-02T22:20:58","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/124691\/"},"modified":"2026-09-02T22:20:58","modified_gmt":"2026-09-02T22:20:58","slug":"dualitybios-adc-efforts-draw-roche-in-potential-1b-deal-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/124691\/","title":{"rendered":"Dualitybio\u2019s ADC efforts draw Roche in potential $1B deal"},"content":{"rendered":"<p>Dualitybio Inc. is getting $45 million up front in a deal with Roche AG\u2019s Genentech unit that could exceed $1 billion upon successful development of next-generation antibody-drug conjugate (ADC) candidates. The collaboration and license agreement centers on the DUPAC, or DualityBio Unique Payload Antibody Conjugate, platform, designed to overcome resistance to older topoisomerase inhibitors-based ADCs.<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/84-bioworld\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/214-deals-and-m-a\" rel=\"nofollow noopener\" target=\"_blank\">Deals and M&amp;A<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/239-cancer\" rel=\"nofollow noopener\" target=\"_blank\">Cancer<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/269-antibody-drug-conjugate\" rel=\"nofollow noopener\" target=\"_blank\">Antibody-drug conjugate<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/393-asia-pacific\" rel=\"nofollow noopener\" target=\"_blank\">Asia-Pacific<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/401-u-s\" rel=\"nofollow noopener\" target=\"_blank\">U.S.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Dualitybio Inc. is getting $45 million up front in a deal with Roche AG\u2019s Genentech unit that could&hellip;\n","protected":false},"author":2,"featured_media":124692,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[6261,941,8086,2112,8568,60816,60817,1360,265,134,4178,60818,2278],"class_list":["post-124691","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-antibody-drug-conjugate","tag-asia-pacific","tag-bioworld","tag-cancer","tag-deals-and-ma","tag-dualitybio-inc","tag-dupac","tag-genentech","tag-oncology","tag-roche","tag-roche-ag","tag-topoisomerase","tag-u-s"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117203782065115469","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=124691"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/124691\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/124692"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=124691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=124691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=124691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}